As of September 30, 2023, cash and cash equivalents were $136.4 million, pro forma for net proceeds from the Company’s IPO in November 2023. Lexeo expects its current cash and cash equivalents, including the net proceeds from the IPO, will be sufficient to fund operations into Q4 2025.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LXEO:
- J.P. Morgan Recommends These 2 ‘Strong Buy’ Stocks With Over 60% Upside Potential
- Lexeo Therapeutics initiated with a Buy at Chardan
- Lexeo Therapeutics initiated with an Outperform at Leerink
- Lexeo Therapeutics initiated with an Outperform at RBC Capital
- Lexeo Therapeutics initiated with a Buy at Stifel